

Personal details

Email: ageretti@gmail.com or geretti@med.uniroma2.it

Profile

Internationally recognised senior academic clinician in infectious diseases, with extensive experience across academia, public-sector healthcare, and the pharmaceutical industry. Expertise spans HIV medicine, viral hepatitis, antiviral therapy, diagnostics, drug resistance, and vaccine-preventable infections in vulnerable populations. Longstanding experience bridging clinical care, translational research, and health policy. Active contribution to guideline development and critical appraisal of evidence to inform public health and regulatory decision-making at national, European, and global levels.

Overview

- Training and professional development in centres of excellence in Italy, the UK, the Netherlands, and Switzerland
- Full Professor of Infectious Diseases since 2011; Senior Specialist Physician since 2001

Expertise domains

- Drug development from first-in-human through subsequent phases
- Translational and clinical research
- HIV therapeutics and clinical management
- Antiviral therapy and drug resistance
- Diagnostic strategies and evaluation
- Vaccines and immunisation in immunocompromised populations
- Guideline and policy development and implementation

Qualifications

- National Qualification as Full Professor (Abilitazione Nazionale Professore Ordinario di Prima Fascia; 06/D4 - malattie cutanee, malattie infettive e malattie dell'apparato digerente), Ministry of Education, Universities & Research (MIUR) [Italy 2022]
- Diploma in the History of Medicine – DHMSA [UK 2024]
- Fellowship Royal College of Pathologists [UK 2008]
- Certificate of Completion of Specialist Training in Virology [UK 2000]
- PhD in Virology, Erasmus University [Netherlands 1997]
- Specialist Diploma in Oncology (*Cum Laude*), Federico II University [Italy 1992]
- Master of Science (MSc) in Immunology (*Distinction*), Royal Postgraduate Medical School [UK 1992]
- Medical Doctorate (*Cum Laude & Double Special Mention*), Federico II University [Italy 1989]

Current Senior Academic and Clinical Roles

Since	Position	Organisation
Sept 2024	Full Professor of Infectious Diseases Role: Academic leadership in translational research, evidence appraisal, mentorship, supervision, and teaching Appointed based on international distinction (per chiara fama)	University of Rome Tor Vergata [Rome, Italy]
May 2023	Senior Specialist in Infection Role: Clinical leadership in complex infectious diseases and implementation of evidence-based practice	Royal Free London NHS Foundation Trust [London, UK]
June 2021	Senior Specialist in Infectious Diseases (rolling contracts, current from Mar 2025)	Fondazione Policlinico Tor Vergata [Rome, Italy]

Other Current Senior Roles

Since	Position	Organisation
Oct 2025	Research Consultant in Infectious Diseases Role: Provide strategic input to research activities within Hepatology	National Institute of Infectious Diseases "Lazzaro Spallanzani" [Rome]
Apr 2021	Visiting Professor in Infectious Diseases	King's College London [London]
Jan 2019	Editor in Chief , Sexually Transmitted Infections	British Medical Journal Group [London]
Jan 2015	Chair , Immunisation Guideline Panel Role: Lead the development and periodic update of graded guidance on the use of immunisation in adults living with HIV, including systematic evidence appraisal	British HIV Association [UK]

Previous Senior Academic and Clinical Roles

From	To	Position	Organisation
Feb 2017	Dec 2023	Expert Scientist in Infectious Diseases Role: Senior project leader for early clinical development of multiple anti-infective and immunomodulatory products, providing scientific and medical leadership to multidisciplinary development teams and leading regulatory-facing evidence generation. In Jan 2021, appointed Head of Virology Early Development , with responsibility for strategic oversight of the clinical virology development portfolio.	Research Innovation Campus, Roche Pharma Research & Early Development [Basel, Switzerland]
Sept 2018	Dec 2019	Director , Academic Clinical Trial Unit Role: Led the unit through the process of obtaining regulatory (MHRA) accreditation	Brighton & Sussex Medical School [Brighton, UK]
Nov 2011	Mar 2021	Professor of Virology & Infectious Diseases and Senior Specialist in Infectious Diseases	University of Liverpool & Royal Liverpool University Hospital [Liverpool, UK]
Aug 2003	Oct 2011	Senior Clinical Lecturer and Senior Specialist in Virology	University College London & Royal Free Hospital [London, UK]
May 2001	Jul 2003	Senior Specialist in Virology and Senior Clinical Lecturer in HIV & Genitourinary Medicine	King's College Hospital & Guy's, King's and St Thomas' Medical School [London, UK]

Latest Publications

A full list of publications is available at: <https://orcid.org/0000-0002-3670-6588>

1. **Geretti AM**, et al. Safety, pharmacokinetics and pharmacodynamics of the antisense oligonucleotide RO7239958 in healthy volunteers and adults with chronic hepatitis B infection. *Antimicrobial Agents Chemother* 2025;69:e0067925.
2. Stockdale AJ, Kreuels B, Shawa IT, Silungwe NM, Mbale B, Chetcuti K, Joekes E, Mallewa J, Tannich E, Weiler-Normann C, Lütgehetmann M, Finch P, Waddilove E, Delphin M, Matthews PC, Thomson EC, **Geretti AM**, Gordon MA. Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case-control study. *Lancet Glob Health* 2025;13:e1924-e1934.

3. Alessio G, Zaće D, Jones C, Lorenzo AD, Imeneo A, Malagnino V, Teti E, Sarmati L, Ruggiero A, Iannetta M, **Geretti AM**. COVID-19 and influenza vaccination among adults stably engaged in HIV care. *Vaccine*: X 2025;27:100719.
4. Llibre JM, Ripamonti D, **Geretti AM**, et al. Emergent HIV-1 drug resistance in randomized trials of contemporary antiretroviral regimens. *Clin Infect Dis* 2025 Sep 23:ciaf471.
5. Kelly C, Lester JS, Bradshaw D, Bibby DF, Mohamed H, Murphy G, Brown A, Sabin C, **Geretti AM**, Mbisa JL. Real-world prevalence of non-integrase INSTI resistance-associated mutations and virological outcomes in people who have recently acquired HIV-1 in the UK. *J Infect Dis* 2025 Sep 26:jiaf500.
6. Orkin C, Paterson A, Elias A, Smuk M, Ring K, Volny-Anne A, Calmy A, Hazra A, **Geretti AM**, et al. Establishing shared definitions of virological failure and discontinuation for long-acting injectable cabotegravir and rilpivirine therapy (the CONSENSUS-LAI Study): an international survey and Delphi process. *Lancet HIV* 2025;12:e649-e659.
7. **Geretti AM**, et al. Optimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care: Evidence, implementation, and unanswered questions. *Open Forum Infect Dis* 2025;12:ofaf368.
8. Iwaji C, Waters L, Milinkovic A, Orkin C, Fox J, Post F, Perry N, Bruce C, Dailey N, To Y, Bremner S, Churchill D, **Geretti AM**. Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study). *Virol J* 2025;22:33.
9. Zaće D, Çekrezi A, Jones C, Ferrari L, De Simone G, Teti E, Malagnino V, Iannetta M, Sarmati L, **Geretti AM**. The evolving landscape of COVID-19: factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance. *BMC Infect Dis* 2025;25:130.
10. Patel R, Moran B, Clarke E, **Geretti AM**, et al. 2024 European guidelines for the management of genital herpes. *J Eur Acad Dermatol Venereol* 2025;39:742-758.



05/01/2026